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I shall begin with two axioms and a few defini-
tions and, subsequently, offer conclusions and a few 
words to the medical lexicon. Axiom # 1-there 
is no such thing as a CV A. In the year 1974, 
with cerebral angiography widely available and with 
computerized axial transverse tomography coming 
into its own, CVA can only stand for "confused 
vascular analysis." Axiom #2-the best time to 
treat a stroke is before it happens or at the very 
least, before it significantly disables the patient. 
Ultimately, there are two fundamental kinds 
of stroke: cerebral infarction or ischemia and cere-
bral hemorrhage. The first relates to a focal cerebral 
dysfunction due to transient or persistent insuffi-
ciency of blood in a given cerebral vascular territory. 
The second relates to the often massive escape of 
blood into the brain parenchyma, the subarachnoid 
space, or both locations. From a practical stand-
point, a lumbar puncture which fails to reveal blood, 
and particularly xanthochromia, effectively rules out 
almost all cerebral hemorrhages and suggests the 
process of cerebral ischemia or infarction. The two 
major kinds of stroke can be differentiated clinically 
without too much difficulty. On the other hand, 
the problems of etiology, pathogenesis, and manage-
ment continue to challenge the clinician. Since 
strokes due to cerebral ischemia and/ or infarction 
account for 75% or more of all observed strokes, 
and because of the preponderance of strokes of this 
variety and the limits of space, we will confine our 
attention here entirely to the problem of cerebral 
ischemia and infarction. 
If one is to classify strokes due to cerebral 
ischemia, one may do so in terms of the nature 
and duration of the episode, on the one hand, and 
the vascular territory of involvement, on the other 
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hand. When an episode of focal cerebral dysfunction 
occurs which is related to a given vascular territory, 
persists for minutes to at most 12-24 hours, and 
then vanishes completely, we say that the patient 
has had a transient ischemic cerebral attack. If the 
episode involves the vision of one or the other eye 
(patients often state that it seemed as though a shade 
was drawn across the vision of the eye), we state 
that the patient has had a transient retinal ischemic 
attack or amaurosis fugax. Onset over a period of 
a few seconds to a few minutes characterizes these 
episodes. If an episode develops either quickly or 
over a period of minutes to hours and if the focal 
deficit persists for many days and then largely but 
not completely clears, we say that the patient has 
had a transient ischemic episode with incomplete 
recovery. From a pathogenic and treatment stand-
point, the transient ischemic episodes and transient 
ischemic episodes with incomplete recovery are 
considered to be a single entity. If the focal deficit 
appears over minutes to hours or sometimes even 
days and persists, severely disabling the patient, we 
say that the patient has suffered from a completed 
stroke. In this situation, cerebral infarction, charac-
teristically, is the underlying cerebral pathology. 
Quite frankly, most neurologists in the field 
at this time can point to no satisfactory treatment 
for the completed stroke, except for good medical 
care with attention to cardiopulmonary function, 
management of blood pressure, withholding of oral 
intake, and treatment entirely by intravenous fluids 
during the acute period, particularly when the pa-
tient is mildly obtunded. These efforts have stood 
the test of time. More specific therapy, such as 
stellate ganglion block and C02 inhalation, as well 
as streptokinase and urokinase, have fallen by the 
wayside, some buried by their own initial advocates. 
Nevertheless, the search must go on. In only one 
area, that of stroke in evolution involving the brain 
stem, has a specific form of therapy, anticoagulation, 
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reduced mortality and morbidity to a degree-ten-
fold-which causes the Mayo group to advocate 
its use with vigor in this specific instance. 
Ischemic strokes are also defined in terms of 
territory of presumed blood vessel involvement. The 
two major territories are those of the carotid middle 
cerebral-anterior cerebral system and the vertebro-
basilar system. Carotid territory dysfunction is char-
acterized by one or more of the following: ipsi-
lateral, transient or rarely persistent visual loss due 
to the fact that the ophthalmic artery is the first 
branch of the carotid artery, contralateral weakness, 
contralateral cortical sensory dysfunction, contra-
lateral hemianopia, and in almost all of the right-
handed individuals and in some 60% of left-handed 
individuals, aphasia or dysphasia-the impairment 
of the faculty of language when the left internal 
carotid artery territory and left cerebral hemisphere 
are involved. The words of the psalmist, "If I forget 
thee, O' Jerusalem, let my right hand forget its 
cunning and let my tongue cleave to the roof of my 
mouth," characterize the classic dominant carotid 
territory lesion. 
Strokes due to vertebrobasilar involvement 
rarely give rise to the classic crossed syndromes so 
familiar in neuroanatomy texts, such as Weber's 
syndrome, characterized by an ipsilateral third nerve 
palsy and a contralateral hemiplegia. More often, one 
or more of the following characterize ischemia in 
the vertebrobasilar territory: alternating hemiparesis , 
ataxia, diplopia, dysarthria, hiccup, alterations in 
respiratory pattern, nausea and vomiting, and pupil-
lary changes. 
Many things can cause transient or persistent 
focal cerebral or retinal ischemia. Particularly when 
ischemia is encountered in younger individuals, one 
may suspect a primary cardiac source involving 
the valves as in rheumatic endocarditis or verrucous 
endocarditis, left atrial thrombosis in rheumatic 
heart disease with mitral stenosis and atrial myxoma. 
Changing pulses and/ or chest pain should suggest a 
dissecting aneurysm. Atrial fibrillation should always 
suggest a primary cardiac source. A variety of sys-
temic diseases including polycythemia, thrombotic 
thrombocytopenic purpura, idiopathic thrombocyto-
sis, and granulomatous angiitis, as well as dissemi-
nated intravascular coagulation should be thought of 
in all cases; but the garden variety of transient or 
persistent stroke due to focal cerebral ischemia, as 
seen in the hospital, usually appears in a seemingly 
healthy male at an average age of 62. The incidence 
of what is still fashionably called "cerebral throm-
bosis" in this patient population approaches 1 % per 
year in the age group 65-74. Almost 40% of these 
patients have a history of increased blood pressure, 
20% a history of diabetes, and at least 50% will give 
a history of a previous transient cerebral ischemic 
episode. Hypertension, diabetes, and previous TIA's 
constitute the triad of the stroke-prone profile; 
indeed, 30-37% of patients with transient ischemic 
episodes will exhibit a full-blown completed stroke 
within five years if untreated. 
Our New York University (NYU) study of 
the surgical treatment of transient and persistent 
focal cerebral ischemia revealed approximately one-
third of the patients with transient ischemic attacks , 
one-third with transient ischemic attacks and incom-
plete recovery, and one-third with completed strokes. 
Arteriographic studies had borne out the fact , first 
extensively studied by Hutchinson and Yates , that 
the garden variety of transient or persistent focal 
cerebral ischemia is related more to observable 
extracranial atheromatous arterial disease, particu-
larly in the carotid arteries than to primary intra-
cranial occlusive disease and indeed, more to steno-
sis than to occlusion. 
Various studies have defined the preferred sites 
of atheromatous disease in the surgically approach-
able areas of the brachiocephalic system. Predomi-
nance of the carotid bifurcation involvement is ap-
parent with stenosis of greater than 30% being 
present in more than one-third of all right and 
one-third of all left carotid arteries. Frank occlusion 
is much less common. In the intracranial circulation, 
observable stenotic lesions in the carotid territory 
fall tenfold. The values for occlusion in the distal 
carotid artery are inflated because in many cases 
occlusion is taken to represent propagation of clot 
from the origin of the internal carotid artery. Proxi-
mal vertebral artery involvement has been seen in 
approximately 20% of all vertebral origins on the 
right and left. Considerably less often, but probably 
symptomatically much more important, is stenosis 
which is seen distally in the vertebrobasilar system. 
There is no clear-cut relationship between 
frank carotid occlusion and the degree of neuro-
logical deficit. Another problem encountered is that 
patients often do not present with a single high 
grade stenotic lesion in the artery appropriate to 
their cerebral symptoms; rather they present with a 
complex mixture of arterial lesions which may give 
rise to the exact same symptomatology. 
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In our NYU experience with 400 patients, we 
tried to group all of the cases into a meaningful 
framework. It is understood that every patient's 
vascular fingerprint is individual and that there are 
almost as many patterns of lesions as there are 
symptomatic patients. It was interesting that when 
we classified a lesion as a lesion, if the stenosis oc-
cupied more than 30% of the vascular lumen in 
any x-ray plane, 17 % of the patients showed no 
lesions which occupied 30% or more of a vessel 
lumen after four-vessel angiqgraphy. The existence 
of this pleomorphic pattern of vascular lesions, 
paired with the fact that 50% of all individuals 
over the age of 50 have a major stenosis of at least 
one of the four major vessels (two carotid and two 
vertebrals, all leading to the brain), and that only 
10% ultimately become symptomatic, offered nu-
merous roadblocks to our eventual understanding 
of the pathogenesis of at least most of the carotid 
territory transient and persistent strokes. 
Until the 1960's, it had been customary to 
attribute the patient's symptoms to the degree of 
stenosis or occlusion of the vessel developing by 
one or more pathogenic processes, which led to 
marked luminal compromise and then , presumably, 
to symptoms which developed in proportion to the 
degree of collateral circulation possessed by the 
patient. Surgical studies compared with angiographic 
observations, however, began to question this 
stenotic theory of pathogenesis of strokes. A new 
concept of pathogenesis, best characterized as the 
embolic theory, arose. 
The sources of arterial emboli from lesions, 
which may occupy less than 30% of the vascular 
lumen formerly considered to be insignificant, were 
as follows : necrotic plaque, clot from ulcer, and 
platelet emboli from ulcer. Ulcerations can easily 
be seen on angiography, in the initial phases asso-
ciated often with high grade stenosis, and the dye 
can also be seen hung up in the ulcer crater. Distal 
propagation of thrombus , significantly compromising 
the internal carotid lumen, can be seen. Radiologic 
evidence from NYU disclosed 24 ulcerative and 22 
irregular lesions at the origin of the internal carotid 
arteries of the neck in the cerebral angiograms of 
71 patients with history of cerebral vascular oc-
clusive disease . Further, the incidence of middle 
cerebral branch occlusion associated with either 
irregular or ulcerative lesions of the extracranial 
carotid arteries was 33%, compared to 16% of 
patients with angiographically "normal" or smoothly 
stenosed extracranial carotid arteries. More and 
more evidence, therefore, implicates the process of 
arterial-arterial embolization as a major one, par-
ticularly in transient and often in persistent focal 
cerebral ischemia. 
Thus we have a process of arterial-arterial 
embolization as distinct from cardiac-cerebral artery 
embolization, which apears to be a major patho-
genic factor in ischemic strokes toward which treat-
ment should be aimed before the stroke occurs, 
when we are warned by the presence of a transient 
episode. Since the term embolus is overextended 
and usually implies cardiac source, muddying our 
thinking about cerebral ischemia, I have Jong felt 
that to require the term "cerebral embolus" to in-
clude in its embrace the widespread process of ar-
terial embolization would be like asking a mouse 
to extend its amorous interests to an elephant; it 
would confound confusion where too much con-
fusion already exists . I have proposed, therefore, 
the acronym, "artarem," to describe an embolus 
which arises in an artery (art-) and lodges in a 
distal artery ( -ar-) by a process of embolization 
(-em) . The process can be described as being 
artaremic. On the other hand, if the embolus, from 
clinical evidence, appears to arise from the heart, 
the term "cardiarem" will serve, and the process of 
heart-to-artery embolization might be described as 
"cardiaremic." Adjectival modifiers such as cerebral 
fibrinoplatelet artarem or myxomatous cerebral car-
diarem could give rise to further diagnostic precision. 
Having noted angiographic and operative evi-
dence of the artaremic process , research began for 
a safe medication which could delay or inhibit the 
first step in fibrinoplatelet emboli. Surgical studies had 
already clearly revealed that the neck lesion often 
was related to visual and cerebral symptoms since 
these symptoms disappeared after surgery, whereas 
control patients who were not surgically treated with 
known similar les ions often developed stroke or 
permanent visual defect. The experience of the 
Cooperative Study of Extracranial Arterial Occlu-
sion showed a tenfold reduction in the appearance 
of frank stroke in the territory of the operated 
artery in the neck. There can be no doubt, therefore, 
that the source of the patient's difficulty was most 
often in the prominent lesion at the carotid bifurca-
tion. Surgery, however, has its drawbacks and ran-
dom studies of surgery have failed to precisely define 
the role of arterial surgery. 
Our own NYU random study reveals one rea-
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son for the confusion. In patients who were not 
randomized, the nonsurgical patients showed a con-
siderably smaller initial long-term survival than the 
surgical patients, suggesting a significant measure 
of surgical selection. Where the patients were ran-
domized, long~term survival was equal in both 
groups; initial surgical mortality, however, was sig-
nificantly greater. 
Our figures show that in patients with full 
recovery from transient cerebral ischemic attacks, 
surgical mortality is down to 3% and long-term 
survival is greater than in the nonsurgical group 
(numbers too small for statistical significance). 
Transient ischemic attacks in patients with incom-
plete recovery are characterized by a greater degree 
of surgical mortality; but in the proportion sur-
viving, a larger percentage survived five years. The 
other major point of the surgical study was that 
in patients with completed stroke, surgical mortality 
is prohibitive, particularly in patients who are ob-
tunded, and long-term survival is significantly better 
in the nonsurgical group. Mortality over the long 
term, however, is not simply a function of cerebral 
vascular disease. Asrnciated atherosclerotic disease 
is characteristic of this group of patients. While the 
major cause of death in the postoperative period 
after surgery is stroke, over the long term, cardiac 
causes account for as many deaths as stroke, and 
the number of deaths in the surgical and the non-
surgical series approach one another. 
Since stroke surgery is prophylactic, the major 
question remains-will stroke surgery in selected 
patients significantly diminish the proportion of 
stroke and significantly improve survival? No data 
from randomized studies have yet settled this issue 
completely satisfactorily. Thus, the search has gone 
on for safe medications which will depress the ten-
dency for fibrinoplatelet emboli to form on ulcerated 
or irregular plaques. Obviously nothing can be done 
for the initial process of disengorgement of gum-
matous and cholesterol material from the broken 
down plaque. Anticoagulants have proven to be 
successful in depressing the number of transient 
ischemic episodes; however, anticoagulants can be 
given only to a reliable, stable patient population, 
and such therapy would be much more successful 
in Rochester, Minnesota for Dr. Millikan's and Dr. 
Whisnaqt's patients than for our patients at Bellevue 
Hospital. 
In the 1960's, Frasier Mustard's group in 
Canada (1, 2) noted inhibition of the platelet 
aggregation release reaction by sulfinpyrazone. Sub-
sequent studies have shown that anti-inflammatory 
drugs, such as butazoladine derivatives and aspirin, 
the pyridopyramidine compounds such as Persan-
tine® and the tricyclic antidepressant drugs, have 
an effect on platelets. The most profound inhibition 
of ADP or collagen-induced platelet aggregation 
is shown by aspirin . In the in vitro studies, 37% of 
serotonin is released with no aspirin, as compared 
to no release with aspirin. A tenfold increase in 
ADP reveals that aspirin can no longer be effective 
against aggregation, but that there is continuing 
inhibition of serotonin release. Similarly, aspirin 
inhibits connective tissue induced aggregation as 
well as serotonin release from platelets. This effect 
of aspirin is not confined only to the test tube, but 
it has been shown in dogs that arterial thrombus 
is retarded when the intimal surface of an artery 
is mechanically or chemically damaged and similar 
results have been shown after endarterectomy in 
patients receiving aspirin ( 3) . While it is known 
that as little as 5 gr of aspirin may depress the 
aggregation release reaction for as long as five days 
in man, as judged by the epinephrine challenge to 
platelet rich plasma as well as with most in vitro 
tests, this association of inhibition of aggregation 
is not clearly related to observed inhibition of tran-
sient ischemic episodes. It has been noted, however, 
that aspirin will stop transient retinal ischemic at-
tacks, amaurosis fugax. We have been able to follow 
a most instructive patient at NYU who had as many 
as nine attacks daily of amaurosis fugax, with re-
sponse to increasing doses of aspirin in terms of 
attacks and effect on platelet aggregation release 
reaction. This unusual patient demonstrated that 
the optimal dose of aspirin for amaurosis fugax 
appears to be 5 gr qid. A retrospective study recently 
published in Stroke by Dy ken ( 3) shows a relative 
diminution of transient cerebral ischemic attacks 
in aspirin-treated patients. It is of interest that in 
some of his cases the attacks responded better to 
four aspirin tablets per day than to two. Prospective 
studies of aspirin, directed toward not only the 
question of aspirin inhibition of transient attacks, 
but also to the more important question of prophy-
laxis against completed stroke, are in process in 
the United States and in Canada and no definitive 
statement will be made on this subject for at least 
another year. 
The judicious mixture of surgical therapy and 
prophylactic therapy with a safe platelet antiag-
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gregant appears at this time to be the best combina-
tion of approaches to the axiom: the best time to 
treat a stroke is before it happens. 
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